Ana Paula Marte Chacra

Ana Paula Marte Chacra

Auto-generated profile, based on publicly available information

Ana Paula Marte Chacra

Instituto do Coração (Incor) do Hospital das Clínicas da Faculdade de medicina da Universidade de são Paulo (HCFMUSP), São Paulo, SP - Brasil

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2022 in Circulation: Genomic and Precision Medicine
Verified
Journal Article
Closed access
PDF file
MTMauricio Teruo Tada
Mauricio Teruo Tada
VRViviane Zorzanelli Rocha
Viviane Zorzanelli Rocha
ILIsabella Ramos Lima
Isabella Ramos Lima
TOThéo Gremen Mimary Oliveira
Théo Gremen Mimary Oliveira
ACAna Paula Chacra
Ana Paula Chacra
APAlexandre Costa Pereira
Alexandre Costa Pereira
Background: Sitosterolemia is a rare autosomal recessive disorder caused by homozygous or compound heterozygous variants in ABCG5/ABCG8 . The disease is characterized by increased plasma plant sterols. Small case series suggest that patients with sitosterolemia have wide phenotypic heterogeneity with great variability on either plasma cholesterol levels or development of atherosclerotic cardiovascular disease. The present study aims to characterize the prevalence and clinical features of sitosterolemia participating in a familial hypercholesterolemia genetic cascade screening program. Methods: From 443 familial hypercholesterolemia index cases, 260 were negative for familial hypercholesterolemia genes and were sequenced for the ABCG5/8 genes. Clinical and laboratory characteristics of affected individuals were determined. Results: Eight (3.1%) index cases were found to be homozygous or compound heterozygous variant for ABCG5/ABCG8 genes, confirming the genetic diagnosis of sitosterolemia. Screening their relatives led to the identification of 6 additional confirmed sitosterolemia cases (3 homozygous and 3 compound heterozygous variant) and 18 carriers (heterozygous). The mean age of identified sitosterolemia cases (n=14) was 37.2±19.8 years, 50% were females, and 78.6% (all adults) presented either clinical or subclinical atherosclerotic cardiovascular disease. As expected, affected individuals presented elevated plasma plant sterol levels (mean β-Sitosterol and campesterol, respectively, 160.3±107.1 and 32.0±19.6 µg/mL) and the highest plasma LDL (low-density lipoprotein)-cholesterol was 269.0±120.0 mg/dL (range: 122–521 mg/dL). LDL-cholesterol mean reduction with therapy among cases was 65%. Eighty-three percent (83%) of identified sitosterolemia patients presented hematologic abnormalities. Conclusions: Testing genes associated with sitosterolemia in the molecular routine workflow of a familial hypercholesterolemia cascade screening program allowed the precise diagnosis of sitosterolemia in a substantial number of patients with varying LDL-C levels and high incidence of early atherosclerotic cardiovascular disease and hematologic abnormalities.

14 July 2017 in Diabetology & Metabolic Syndrome
Verified
Journal Article
Open access
PDF file
MBMarcello Casaccia Bertoluci
Marcello Casaccia Bertoluci
RMRodrigo Oliveira Moreira
Rodrigo Oliveira Moreira
AFAndré Faludi
André Faludi
Maria Cristina IzarMaria Cristina Izar
Maria Cristina Izar
BSBeatriz Schaan
Beatriz Schaan
RSRaul D Santos
Raul D Santos
Since the first position statement on diabetes and cardiovascular prevention published in 2014 by the Brazilian Diabetes Society, the current view on primary and secondary prevention in diabetes has evolved as a result of new approaches on cardiovascular risk stratification, new cholesterol lowering drugs, and new anti-hyperglycemic drugs. Importantly, a pattern of risk heterogeneity has emerged, showing that not all diabetic patients are at high or very high risk. In fact, most younger patients who have no overt cardiovascular risk factors may be more adequately classified as being at intermediate or even low cardiovascular risk. Thus, there is a need for cardiovascular risk stratification in patients with diabetes. The present panel reviews the best current evidence and proposes a practical risk-based approach on treatment for patients with diabetes. The Brazilian Diabetes Society, the Brazilian Society of Cardiology, and the Brazilian Endocrinology and Metabolism Society gathered to form an expert panel including 28 cardiologists and endocrinologists to review the best available evidence and to draft up-to-date an evidence-based guideline with practical recommendations for risk stratification and prevention of cardiovascular disease in diabetes. The guideline includes 59 recommendations covering: (1) the impact of new anti-hyperglycemic drugs and new lipid lowering drugs on cardiovascular risk; (2) a guide to statin use, including new definitions of LDL-cholesterol and in non-HDL-cholesterol targets; (3) evaluation of silent myocardial ischemia and subclinical atherosclerosis in patients with diabetes; (4) hypertension treatment; and (5) the use of antiplatelet therapy. Diabetes is a heterogeneous disease. Although cardiovascular risk is increased in most patients, those without risk factors or evidence of sub-clinical atherosclerosis are at a lower risk. Optimal management must rely on an approach that will cover both cardiovascular disease prevention in individuals in the highest risk as well as protection from overtreatment in those at lower risk. Thus, cardiovascular prevention strategies should be individualized according to cardiovascular risk while intensification of treatment should focus on those at higher risk.

27 September 2021 in Arquivos Brasileiros de Cardiologia
Verified
Journal Article
Open access
PDF file
Maria Cristina IzarMaria Cristina Izar
Maria Cristina Izar
VGViviane Zorzanelli Rocha Giraldez
Viviane Zorzanelli Rocha Giraldez
ABAdriana Bertolami
Adriana Bertolami
RSRaul D Santos
Raul D Santos
ALAna Maria Lottenberg
Ana Maria Lottenberg
WSWilson Salgado
Wilson Salgado
Introdução A hipercolesterolemia familiar (HF) é uma causa genética comum de doença coronariana prematura, especialmente de infarto do miocárdio, devido à exposição ao longo da vida a concentrações elevadas de colesterol da lipoproteína de baixa densidade (LDL-c). Caracteriza-se por ser uma forma grave de dislipidemia de base genética, em que aproximadamente 85% dos homens e 50% das mulheres podem ter um evento coronariano antes de completar os 65 anos de idade, se não tratados adequadamente. A HF é considerada um [...] Introdução A hipercolesterolemia familiar (HF) é uma causa genética comum de doença coronariana prematura, especialmente de infarto do miocárdio, devido à exposição ao longo da vida a concentrações elevadas de colesterol da lipoproteína de baixa densidade (LDL-c). Caracteriza-se por ser uma forma grave de dislipidemia de base genética, em que aproximadamente 85% dos homens e 50% das mulheres podem ter um evento coronariano antes de completar os 65 anos de idade, se não tratados adequadamente. A HF é considerada um

1 February 2021 in Atherosclerosis
Verified
Journal Article
Closed access
ECElaine R. Coutinho
Elaine R. Coutinho
MMMarcio H. Miname
Marcio H. Miname
VRViviane Z. Rocha
Viviane Z. Rocha
MBMarcio S. Bittencourt
Marcio S. Bittencourt
CJCinthia E. Jannes
Cinthia E. Jannes
RSRaul D Santos
Raul D Santos

1 October 2020 in Arteriosclerosis, Thrombosis, and Vascular Biology
Verified
Journal Article
Closed access
Ana Catarina AlvesAna Catarina Alves
Ana Catarina Alves
RARodrigo Alonso
Rodrigo Alonso
JDJose luis Díaz Díaz
Jose luis Díaz Díaz
AMAna Margarida Medeiros
Ana Margarida Medeiros
CJCinthia E Jannes
Cinthia E Jannes
RSRaul D Santos
Raul D Santos
Characterize homozygous familial hypercholesterolemia (HoFH) individuals from Iberoamerica. Approach and Results: In a cross-sectional retrospective evaluation 134 individuals with a HoFH phenotype, 71 adults (age 39.3±15.8 years, 38.0% males), and 63 children (age 8.8±4.0 years, 50.8% males) were studied. Genetic characterization was available in 129 (96%). The majority (91%) were true homozygotes (true HoFH, n=79, 43.0% children, 46.8% males) or compound heterozygotes (compound heterozygous familial hypercholesterolemia, n=39, 51.3% children, 46.2% males) with putative pathogenic variants in the LDLR. True HoFH due to LDLR variants had higher total (P=0.015) and LDL (low-density lipoprotein)-cholesterol (P=0.008) compared with compound heterozygous familial hypercholesterolemia. Children with true HoFH (n=34) tended to be diagnosed earlier (P=0.051) and had a greater frequency of xanthomas (P=0.016) than those with compound heterozygous familial hypercholesterolemia (n=20). Previous major cardiovascular events were present in 25 (48%) of 52 children (missing information in 2 cases), and in 43 (67%) of 64 adults with LDLR variants. Children who are true HoFH had higher frequency of major cardiovascular events (P=0.02), coronary heart (P=0.013), and aortic/supra-aortic valve diseases (P=0.022) than compound heterozygous familial hypercholesterolemia. In adults, no differences were observed in major cardiovascular events according to type of LDLR variant. From 118 subjects with LDLR variants, 76 (64%) had 2 likely pathogenic or pathogenic variants. In 89 subjects with 2 LDLR variants, those with at least one null allele were younger (P=0.003) and had a greater frequency of major cardiovascular events (P=0.038) occurring at an earlier age (P=0.001). There was a high frequency of cardiovascular disease even in children. Phenotype and cardiovascular complications were heterogeneous and associated with the type of molecular defect.

13 October 2025 in Arquivos Brasileiros de Cardiologia
Verified
Journal Article
Open access
FRFabiana Hanna Rached
Fabiana Hanna Rached
MMMarcio Hiroshi Miname
Marcio Hiroshi Miname
VRViviane Zorzanelli Rocha
Viviane Zorzanelli Rocha
AZAndré Zimerman
André Zimerman
FCFernando Henpin Yue Cesena
Fernando Henpin Yue Cesena
JSJose Saraiva
Jose Saraiva